NASDAQ:ADMA
ADMA Biologics Inc Stock News
$6.81
+0.0700 (+1.04%)
At Close: May 03, 2024
ADMA Biologics: Significant Derisking, Product Launches In Second Half Of The Year
04:05pm, Tuesday, 28'th May 2019
Shares have lost over a third of their value during the past three years.
ADMA Biologics: Under-The-Radar Biotech With Huge Potential Upside
12:33am, Wednesday, 22'nd May 2019
Since April, ADMA has won approval for two IVIG products, Asceniv and Bivigam, as well as approval to manufacture them in its vertically integrated facility.
The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
08:19am, Wednesday, 03'rd Apr 2019
Here's a roundup of top developments in the biotech space over the last 24 hours.
ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy
10:26am, Tuesday, 02'nd Apr 2019
Microcap specialty pharma company ADMA Biologics Inc. advanced in the last two trading days in anticipation of a binary event, and with the event materializing in favor of the company, the stock has t
ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment
09:00am, Tuesday, 02'nd Apr 2019
Shares of ADMA Biologics Inc. rocketed 54% in very active premarket trade Tuesday.
ADMA Biologics Investors Prepare For RI-002 PDUFA
09:09am, Monday, 01'st Apr 2019
Back on December 19th, ADMA Biologics (ADMA) received a complete response letter "CRL" from the FDA concerning their PAS for BIVIGAM.
